Read by QxMD icon Read

Cardiovascular & Hematological Disorders Drug Targets

Antonio Girolami, Diana Noemi Garcia de Paoletti, Marcelo Leonardo Nenkies, Silvia Ferrari, Hugo Guglielmone
A compound heterozygote due to the association of a new mutation (Gla72Asp) with an already known mutation (Gly154Arg) of the FX gene is reported. The proposita is a 38 year old female who had a moderate bleeding tendency (menorrhagia, epistaxis, easy bruising). The proposita has never received substitution therapy but in the occasion of a uterine biopsy. The mother was asymptomatic but was a heterozygote for the new mutation. The father was asymptomatic but had deserted the family and could not be investigated...
December 11, 2018: Cardiovascular & Hematological Disorders Drug Targets
Habib Haybar, Saeid Shahrabi, Mohammad Shahjahani, Hadi Rezaeeyan
Development of cardiomyopathy (CM) is dependent upon several factors. However, reaction of immune response against myocardial tissue due to microbial and viral infections plays an important role in this disease. Therefore, the purpose of this study is to investigate the relationship between HLAs and their pathogenic mechanisms in the incidence of CM. Relevant literature was identified by a PubMed search (1989-2017) of English-language papers using the terms "Cardiomyopathy", "Human leukocyte antigen or HLA", "immune response", and "polymorphism"...
December 5, 2018: Cardiovascular & Hematological Disorders Drug Targets
W Serra, A Fantin, C Longo, G Rabia, F De Rosa, C Plenteda, F Re, E Crisafulli, A Chetta
Carfilzomib, a proteasome inhibitor, known as a therapeutical option for people who have already received one or more previous treatments for multiple myeloma, has well known cardiac and systemic adverse effects. There is evidence supporting that adverse effects are dose-dependent, yet there is no known patient phenotype characterized by worse associated consequences, nor are there widely accepted monitoring protocols. In this article we describe two patients with cardiovascular adverse events related to carfilzomib treatment and their clinical course...
December 4, 2018: Cardiovascular & Hematological Disorders Drug Targets
Habib Haybar, Saeed Alipour Parsa, Isa Khaheshi, Zeinab Deris Zayeri
AIM: To examine if pentraxin can help identifying patients benefitting most from primary Percutaneous Coronary Intervention (PCI) vs. fibrinolysis. METHODS: Patients with acute ST-Elevation Myocardial Infarction (STEMI) were consecutively recruited from a community center without PCI and a tertiary center with PCI facilities.Left ventricular ejection fraction (LVEF) was determined echocardiographically at baseline and 5 day after the index admission; the difference between two measurements was considered as the magnitude of improvement...
November 20, 2018: Cardiovascular & Hematological Disorders Drug Targets
Parisa Sadighara, Atefeh Araghi, Behrouz Tajdar-Oranj, Leila Peivasteh Roudsari, Afsaneh Mohajer, Ramezan Behzadi
BACKGROUND: there has been considerable interest in the potential health benefits of borage. Little information is available regarding safety of this plant. The purpose of this study was to evaluate the impact of borage on the mouse heart. METHODS: Different amounts of borage extract were injected on mice. The mice randomly divided into 4 group including group1 (Control group without injection), group2, 3 and 4 that received 12.5 mg/kg, 25 mg/kg and 50 mg/kg respectively...
November 4, 2018: Cardiovascular & Hematological Disorders Drug Targets
Trevor Simard, Richard Jung, Alisha Labinaz, Mohammad Ali Faraz, F Daniel Ramirez, Pietro Di Santo, Ian Pitcher, Pouya Motazedian, Chantal Gaudet, Rebecca Rochman, Jeffrey Marbach, Paul Boland, Kiran Sarathy, Saleh Alghofaili, Juan J Russo, Etienne Couture, Robert S Beanlands, Benjamin Hibbert
Adenosine, a purine nucleoside, is produced broadly and implicated in the homeostasis of many cells and tissues. It signals predominantly via 4 purinergic adenosine receptors (ADORs) - ADORA1, ADORA2A, ADORA2B and ADORA3 in addition to non-ADOR mediated effects. Through these signaling mechanisms, adenosine exerts effects on numerous cell types crucial to maintaining vascular homeostasis, especially following vascular injury. Both in vitro and in vivo models have provided considerable insights into adenosine signaling and identified targets for therapeutic intervention...
October 10, 2018: Cardiovascular & Hematological Disorders Drug Targets
Tahereh Farkhondeh, Saeed Samarghandian, Mohsen Azimi-Nezhad, Ali Mohammad Pourbagher Shahri
Curcumin, is the major phenolic compound the rhizome of the Curcuma species that is used in herbal medicine. Several studies has showed the protective effects of curcumin against nephrotoxi agents such as gallic acid, glucose, tartrazine, streptozotocin, lead, maleate, malathion, nicotine, cisplatin, gentamicin and methotrexate. However, due to the lake of linical trial studies, more investigation are needed to determine the efficacy of curcumin as an antidote agent. The present study aimed to critically review the recent literature data from that regarding the protective effects of curcumin against nephrotoxin agents...
September 5, 2018: Cardiovascular & Hematological Disorders Drug Targets
Surya Prakash Pandey, Prasoon Madhukar, Priya Dev, Deepika Joshi, Vijay Nath Mishra, Rameshwar Nath Chaurasia, Abhishek Pathak
Background Blood biomarkers are a cost-effective and valid method to diagnose ischemic stroke and differentiate it's subtypes in countries with poor resources. Objective To perform a systematic review of published literature evaluating diagnostic utility of blood based biomarkers to diagnose and differentiate etiology of ischemic stroke. Methods A comprehensive literature search was carried out till December 2017 in major scientific and medical databases including PubMed, Cochrane, OVID and Google Scholar. Modified Quality Assessment of Diagnostic Accuracy Studies questionnaire was used to assess methodological quality of each study...
August 29, 2018: Cardiovascular & Hematological Disorders Drug Targets
Dimitris Kounatidis, Natalia Vallianou, Vasiliki Daskalaki, Christos Masaoutis, Evangelia Margellou, Nikos Harhalakis, Evangelos Kokkinakis
Pure red cell aplasia (PRCA) is a clinical entity comprising severe normochromic normocytic anemia, reticulocytopenia, erythroblastopenia in the bone marrow, with normal leukocyte and platelets count. PRCA can be classified into congenital and acquired, with the latter characterized as idiopathic or secondary to various infections, hematological malignancies, collagen vascular diseases, thymoma, and exposure to a variety of drugs and other chemical substances. Herein, we present a female patient, who presented with PRCA due to azathioprine treatment...
August 28, 2018: Cardiovascular & Hematological Disorders Drug Targets
Bashir M Matata, Maqsood M Elahi
BACKGROUND: Left ventricular hypertrophy and myocardial remodelling occur with aortic valve disease and may lead to heart failure. Although increased oxidative stress and inflammatory factors have been implicated in heart failure, their role in the progression of valve disease remains unclear. OBJECTIVES: We investigated the role of oxidative stress and inflammatory factors in valve disease whether this relates to cell death. METHODS: Blood samples were taken from 24 patients with valve disease before surgery and the results were compared with those from blood samples from 30 control healthy subjects...
July 22, 2018: Cardiovascular & Hematological Disorders Drug Targets
Luis Enrique Cobos-Puc, Hilda Aguayo-Morales
Clonidine is a centrally acting antihypertensive drug. Hypotensive effect of clonidine is mediated mainly by central a2-adrenoceptors and/or imidazoline receptors located in a complex network of the brainstem. Unfortunately, clonidine produces side effects such as sedation, mouth dry, and depression. Moxonidine and rilmenidine, compounds of the second generation of imidazoline drugs, with fewer side effects, display a higher affinity for the imidazoline receptors compared with a2-adrenoceptors. The antihypertensive action of these drugs is due to inhibition of the sympathetic outflow primarily through central I1-imidazoline receptors in the RVLM, although others anatomical sites and mechanisms/receptors are involved...
June 29, 2018: Cardiovascular & Hematological Disorders Drug Targets
Rahul Mittal, Vasanti M Jhaveri, Sae-In Samantha Kay, Patricia Blackwelder, Kunal Patel
BACKGROUND: Cardiovascular diseases such as endocarditis are the second most common cause of death worldwide. Infective endocarditis (IE) is the most serious and fatal infection of the heart associated with significant mortality and morbidity. The interaction of pathogens with human aortic endothelial cells (HAECs) plays a crucial role in the pathogenesis of IE. OBJECTIVE: Pseudomonas aeruginosa is an emerging pathogen that has been associated with IE. However, it is not known whether P...
June 10, 2018: Cardiovascular & Hematological Disorders Drug Targets
Ota Fuchs
No abstract text is available yet for this article.
May 21, 2018: Cardiovascular & Hematological Disorders Drug Targets
Amrita Sarkar, Khadija Rafiq
Cardiovascular disease (CVD) is a class of diseases that involve disorders of heart and blood vessels, including: hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular disease, which finally lead to heart failure (HF). There are several treatments available all over the world, but still CVD and heart failure became the number one problem causing death every year worldwide. Both experimental and clinical studies have shown a role for inflammation in the pathogenesis of heart failure...
May 17, 2018: Cardiovascular & Hematological Disorders Drug Targets
Maurizio Bussotti, Giovanni Marchese
The effects of hypoxia on the human organism has been considered doubly fascinating by the scientific community: the knowledge of the discrete mechanisms allowing the acclimatization both at the genetic level or through the cell mediators production in addition to the macroscopic responses of the cardio-circulatory and ventilatory systems to a hypoxic environment has been progressively developed since the last century; moreover granting a safer stay in hypoxic conditions not only for the residents but also for the different cathegories of workers, sportsmen and tourists has been considered a worthy aim of the medical activity...
May 17, 2018: Cardiovascular & Hematological Disorders Drug Targets
E Suguna, R Farhana, E Kanimozhi, P SaiKumar, G Kumaramanickavel, Chitralekha Sai Kumar
Background &Objective: Acute myeloid leukemia (AML) is characterized by accumulation of ?20% myeloid premature blast cells in the bone marrow and most often found in the peripheral blood. AML is generally classified based on two groups, namely, French-American-British (FAB) and World Health Organization (WHO) systems. For better clinical management, cytogenetic findings in AML are necessary and in patients with normal karyotypes, molecular analysis becomes critical. Mutations of certain genes like Nucleophosmin 1gene (NPM1), Fms-related Tyrosine Kinase 3 (FLT3), CCAAT/Enhancer Binding Protein Alpha (CEBPA), Runt-related transcription factor 1(RUNX1), and Mixed Lineage Leukemia (MLL) play a crucial role in the risk management and clinical stratification of AML patients...
May 15, 2018: Cardiovascular & Hematological Disorders Drug Targets
Suna Aydin, Zekiye Catak, Mehmet Nesimi Eren, Suleyman Aydin, Askin Ender Topal
INTRODUCTION: In coronary bypass surgery, after cardiopulmonary bypass is initiated by arterial cannulation in the ascending aorta and venous cannulation through a single vein generally in the right atrium, the process of cooling the patient is started. There is a relation between cooling the patient and irisin, which is responsible for releasing heat. OBJECTIVE: Therefore, the main objective of the present study is to explore how irisin concentrations and some other panel of myocardium injury in patients undergoing coronary artery bypass surgery changes...
May 11, 2018: Cardiovascular & Hematological Disorders Drug Targets
Karthika Nellaiappan, Veera Ganesh Yerra, Ashutosh Kumar
Macrovascular complications of diabetes like cardiovascular diseases appear to be one of the leading causes of mortality. Current therapies aimed at counteracting the adverse effects of diabetes on cardiovascular system are found to be inadequate. Hence, there is growing need in search of novel targets. Adenosine monophosphate activated protein kinase (AMPK) is one such promising target, as a plethora of evidences point to its cardioprotective role in pathological milieu like cardiac hypertrophy, atherosclerosis and heart failure...
May 7, 2018: Cardiovascular & Hematological Disorders Drug Targets
Rahul Mittal, Vasanti M Jhaveri, Sae-In Samantha Kay, Aubrey Greer, Kyle J Sutherland, Hannah S McMurry, Nicole Lin, Jeenu Mittal, Arul K Malhotra, Amit P Patel
Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality worldwide. The underlying pathology for cardiovascular disease is largely atherosclerotic in nature and the steps include fatty streak formation, plaque progression and plaque rupture. While there is optimal drug therapy available for patients with CVD, there are also underlying drug delivery obstacles that must be addressed. Challenges in drug delivery warrants further studies for the development of novel and more efficacious medical therapies...
May 7, 2018: Cardiovascular & Hematological Disorders Drug Targets
Purnima Gupta, Evelyn Garcia, Amrita Sarkar, Sumit Kapoor, Khadija Rafiq, Hitendra S Chand, Madhavan Nair, Rahul Dev Jayant
Nanotechnology has gained increased attention for delivering therapeutic agents effectively to the cardiovascular system. Heart targeted nanocarrier based drug delivery is a new, effective and efficacious approach for treating various cardiac related disorders such as atherosclerosis, hypertension, and myocardial infarction . Nanocarrier based drug delivery system circumvents the problems associated with conventional drug delivery systems, including their non-specificity, severe side effects and damage to the normal cells...
May 7, 2018: Cardiovascular & Hematological Disorders Drug Targets
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"